common.skip_to_content
USE CODE MUNCHMAKERS FOR 10% OFF YOUR FIRST ORDER (650) 955-1836 Open now · until 5pm PT | REQUEST A CALLBACK
USE MUNCHMAKERS FOR 10% OFF YOUR FIRST ORDER

ICBC Berlin Conference Targets Cross-Border Cannabis Expansion

International event focuses on pharmaceutical production and export markets as global cannabis trade accelerates

The International Cannabis Business Conference (ICBC) is positioning its Berlin event as a primary networking hub for companies pursuing cross-border cannabis opportunities, particularly in pharmaceutical-grade production and medical exports.

The conference comes as European nations continue expanding medical cannabis frameworks and international trade routes open between licensed producers. Germany's recent adult-use reforms and ongoing medical market expansion have made it a focal point for global operators.

"The regulatory landscape in Europe is creating real opportunities for pharmaceutical-grade cannabis production that didn't exist five years ago," said Alex Rogers, ICBC's director of international programs. "Companies with GMP certification are finding export markets across multiple continents."

The Numbers

Global medical cannabis exports reached $580 million in 2023, up 34% from the previous year, according to industry data. The pharmaceutical-grade segment accounts for roughly 60% of that total, with Germany, Israel, and Australia as primary import markets.

European medical cannabis patient numbers grew to approximately 680,000 registered users across 20 countries by late 2023. Germany alone added 140,000 new patients in the past 18 months.

Beyond Cultivation

The ICBC program emphasizes opportunities in sectors beyond traditional cultivation and retail. Genetics companies are seeing increased demand for stable, pharmaceutical-grade cultivars. Processing and extraction firms are expanding into markets where flower sales remain restricted but derivative products are permitted.

Distribution and logistics providers face growing demand as cross-border medical cannabis shipments increase. Technology companies are developing compliance software, track-and-trace systems, and laboratory testing equipment tailored to international regulatory requirements.

"The ancillary services sector is where we're seeing the most investment interest right now," Rogers noted. "These companies can operate across multiple jurisdictions without touching the plant."

Regulatory Complexity

International cannabis operators must navigate a patchwork of national regulations, import permits, and quality standards. The pharmaceutical model requires GMP certification, extensive testing protocols, and compliance with narcotic control treaties.

Several countries maintain medical-only frameworks while prohibiting adult-use sales, creating distinct market dynamics from North American cannabis industries. Pricing structures often reflect pharmaceutical reimbursement models rather than consumer retail markets.

What's Next

The ICBC Berlin conference runs April 10-12, 2025, with sessions covering European regulatory developments, export licensing requirements, and emerging markets in Asia-Pacific and Latin American regions.

Industry observers expect continued growth in medical cannabis exports as more countries establish import frameworks. The pharmaceutical-grade segment is projected to reach $1.2 billion in global trade by 2027, though regulatory barriers remain significant in many jurisdictions.

Companies pursuing international expansion are focusing on markets with established medical frameworks and clear import pathways, rather than speculating on potential adult-use reforms.


This article is based on original reporting by ganjapreneur.com.

More from Maya Patel